Contact & Appointment Information
- 55 Fruit Street
- Boston, MA 02114
- Phone: 617-726-5130
Department: Oncology
About Dr. Alice T. Shaw, MD, PhD
Academic Excellence and Medical Training
Dr. Alice T. Shaw’s school path shows top medical and science training.
She got her MD and PhD from Harvard Medical School, a top school. The dual program built her skills in clinical care and research.
Dr. Alice T. Shaw did her internal medicine residency at Massachusetts General Hospital. There, she gained skill in hard cases and cancer care.
She trained in fellowships at Dana-Farber Cancer Institute and Massachusetts General Hospital. She focused on medical oncology and lung tumors. Both places lead in cancer work and new treatments.
Clinical Focus: Treating Complex Lung Cancers
Dr. Alice T. Shaw treats lung cancer, mainly non-small cell lung cancer, NSCLC. It counts as one of the hardest cancers.
Her skills cover targeted drugs for lung cancers with clear genes, like those from:
ALK gene changes, ROS1 gene joins, Other driver gene shifts in NSCLC
She pushes personalized medicine that fits a tumor’s gene makeup. This beats old chemotherapy for results.
Pioneering Research in ALK and ROS1-Positive Lung Cancer
Dr. Alice T. Shaw’s key work covers ALK and ROS1 changes in lung cancer.
These gene shifts drive tumor growth. Her studies help:
Spot how they work in NSCLC. Build drugs to stop them. Learn why tumors fight back against drugs
Her efforts aid new targeted drugs now used worldwide.
Understanding and Overcoming Drug Resistance
Dr. Shaw studies acquired resistance. Cancer responds at first, then resists.
She looks at how lung cancer cells change under drug stress. She finds the main ways tumors dodge targeted drugs.
Her results spark:
Next ALK blocker drugs Drug mix plans, Trials for new anti-resistance drugs
This lengthens life for advanced lung cancer patients. It shapes global care rules.
Leadership in Translational Oncology
Experts see Dr. Shaw as a top name in translational oncology. It links lab work to patient bedsides.
She aims to shift findings from lab to clinic fast and safely.
She teams with gene experts, trial doctors, and drug makers. They make science into real patient options.
Clinical Trials and Global Impact
Dr. Shaw designs and runs trials for new lung cancer drugs.
Trials test:
First ALK blockers ROS1 drugs Resistance in late NSCLC Drug mixes
Her trial work gets life-saving drugs approved. It sets new care standards in thoracic oncology.
Research Funding and Scientific Recognition
Academic Role and Teaching at Harvard Medical School
As an Associate Professor at Harvard Medical School, Dr. Shaw trains future oncologists and physician-scientists.
She teaches:
Molecular oncology and targeted drugs, Trial design and results, Precision care in cancer, Lab-to-clinic methods
Her students now lead oncology teams in the US and abroad.
Board Certification and Professional Credentials
Dr. Shaw holds a Medical Oncology certification from the American Board of Internal Medicine. It proves her cancer care skills.
Her background sets her as a top lung cancer expert in the clinic and research.
Awards and Honors
Dr. Shaw earns praise for cancer research and patient care.
Awards mark her role in science findings and clinical advances, key to targeted lung therapies.
She leads thought in precision oncology and ALK/ROS1 work.
Patient Care Philosophy: Precision, Hope, and Innovation
Dr. Shaw commits to better lives for lung cancer patients.
Her care stresses:
Treatments matched to tumor genes. Kind talks with patients and families. Trial access in care Plans for long-term control
Her work brings hope, even when standard drugs fail.
A Record of Changing Lung Cancer Care
Dr. Alice T. Shaw has changed how doctors handle lung cancer during her career.
Her studies on ALK and ROS1 cancers created treatments that save lives. They help thousands of patients live longer and feel better around the world.
She blends solid science with top patient care. This shifts lung cancer from a sure death sentence to a condition many can control and treat.
Wrap-Up: A Top Name in Targeted Cancer Care
Dr. Alice T. Shaw shows the best in today’s medical schools. Research, patient care, and teaching join to improve health.
Her job at Massachusetts General Hospital and Harvard Medical School tests new limits in cancer care.
She works hard to grasp cancer’s gene causes and beat drug resistance. This shapes oncology’s path ahead.
Dr. Shaw leads worldwide in targeted medicine. She brings hope, new ideas, and strong science to lung cancer battles.
FAQs
Q. Who is Dr. Alice T. Shaw?
Dr. Alice T. Shaw leads in chest cancer care. She is a doctor-scientist and Associate Professor of Medicine at Harvard Medical School. She focuses on lung cancer studies and targeted drugs.
Q. What are ALK and ROS1 in lung cancer?
ALK and ROS1 are gene changes that fuel cancer growth in some lung patients. Drugs can hit these targets.
Q. Does Dr. Shaw do research?
Yes. She leads global work in lab-to-patient cancer studies and lung drug creation.
Q. Why does Dr. Shaw matter in cancer care?
Her work built drugs that extend lives for lung cancer patients everywhere.